Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CYCLOBENZAPRINE Cause Pemphigus? 158 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 158 reports of Pemphigus have been filed in association with CYCLOBENZAPRINE (Cyclobenzaprine hydrochloride). This represents 1.7% of all adverse event reports for CYCLOBENZAPRINE.

158
Reports of Pemphigus with CYCLOBENZAPRINE
1.7%
of all CYCLOBENZAPRINE reports
156
Deaths
89
Hospitalizations

How Dangerous Is Pemphigus From CYCLOBENZAPRINE?

Of the 158 reports, 156 (98.7%) resulted in death, 89 (56.3%) required hospitalization, and 91 (57.6%) were considered life-threatening.

Is Pemphigus Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CYCLOBENZAPRINE. However, 158 reports have been filed with the FAERS database.

What Other Side Effects Does CYCLOBENZAPRINE Cause?

Toxicity to various agents (1,854) Pain (1,494) Completed suicide (1,438) Drug hypersensitivity (1,094) Constipation (1,057) Drug ineffective (954) Drug abuse (873) Off label use (800) Fall (796) Hypotension (769)

What Other Drugs Cause Pemphigus?

RITUXIMAB (8,574) ABATACEPT (8,441) METHOTREXATE (8,414) PREDNISONE (8,260) LEFLUNOMIDE (8,252) TOCILIZUMAB (8,210) FOLIC ACID (8,128) ADALIMUMAB (8,079) CETIRIZINE (8,063) HYDROXYCHLOROQUINE (8,051)

Which CYCLOBENZAPRINE Alternatives Have Lower Pemphigus Risk?

CYCLOBENZAPRINE vs CYCLOPENTOLATE CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE FOR , USP CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE\DOXORUBICIN\PREDNISONE\RITUXIMAB\VINCRISTINE CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE\DOXORUBICIN\PREDNISONE\VINCRISTINE

Related Pages

CYCLOBENZAPRINE Full Profile All Pemphigus Reports All Drugs Causing Pemphigus CYCLOBENZAPRINE Demographics